Re-mark
Intrahepatic Cholangiocarcinoma market share & size Analysis Intrahepatic Cholangiocarcinoma (ICCA) is a subtype of cholangiocarcinoma, a rare and heterogeneous malignant neoplasm with the epithelial cell origin of the biliary duct and histologic and biochemical features of cholangiocyte differentiation. In 2017, the market size of Intrahepatic Cholangiocarcinoma (ICCA) in the 7MM was USD 99.78 million. The total incident population of Intrahepatic Cholangiocarcinoma (ICCA) in 7MM was 10,177 in 2017. The incident cases of ICCA in the US were found to be 3,639 while Italy and Germany had 1,111 and 1,101 incident cases of ICCA. Some of the key companies in the Intrahepatic Cholangiocarcinoma (ICCA) market include Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Loxo Oncology, QED Therapeutics, Janssen Pharmaceutical, Taiho Oncology, RedHill Biopharma, GlaxoSmithKline, Merck, Eisai, Taiho Pharmaceutical, Sorrento Therapeutics, Yuhan Corporation, Hutchison Medipharma, Jiangsu HengRui Medicine, AstraZeneca, Eli Lilly, Servier Laboratories, Genoscience Pharma, Forma Therapeutics, and Array BioPharma.
You may like
Matte Visiting Cards
#MatteVisitingCards, #MatteFinish, #ElegantBusinessCards, #SmoothTouch, #PremiumQuality, #CustomMatteCards, #ModernDesign
Glossy Business Cards
#GlossyBusinessCards, #HighGlossFinish, #ShinyBusinessCards, #LuxuryVisitingCards, #PremiumPrinting, #ProfessionalDesign, #VibrantColors
Eco-Friendly Business Card
#EcoFriendlyBusinessCards, #SustainableDesign, #RecycledPaperCards, #GreenPrinting, #EcoBranding, #BiodegradableCards, #EnvironmentFriendly